With reference to the antimalarial drug mefloquine administered to Canadian Forces bound for Somalia in 1992-93 and the legal framework under which it was available for use and administered: ( a ) was mefloquine a licensed drug when it was administered to Canadian Forces, if not what was its status, and how was it legally available; ( b ) were the Canadian Forces participating in the Lariam (mefloquine) Safety Monitoring Study during this period; ( c ) was the mefloquine administered in accordance with the Lariam Safety Monitoring Study and the Food and Drug Act; ( d ) who was the “principal investigator” responsible for the Lariam Safety Monitoring Study in the Canadian Forces; ( e ) who was the Canadian Forces physician responsible to the “principal investigator” of the Lariam Safety Monitoring Study; ( f ) what was the role of Canadian Forces physician, Dr. Martin Tepper, in the Lariam Safety Monitoring Study; ( g ) who was responsible for the Lariam Safety Monitoring Study at the Department of Health's Health Protection Branch during this period; ( h ) what was the role and responsibility of the Health Protection Branch under the Lariam Safety Monitoring Study and the Food and Drug Act and its regulations in regard to the use of mefloquine by Canadian Forces personnel; ( i ) when did the Health Protection Branch become aware that mefloquine was being administered to Canadian Forces personnel bound for Somalia; ( j ) what responsibility did the Canadian Forces have under the Lariam Safety Monitoring Study and the Food and Drug Act prior to the licensing of mefloquine to inform the manufacturer of its use; ( k ) what responsibility did the Canadian Forces have under the Lariam Safety Monitoring Study and the Food and Drug Act to the soldiers who were administered the drug; ( l ) did the Canadian Forces fulfil their responsibility to the manufacturer under the Lariam Safety Monitoring Study and the Food and Drug Act prior to the licensing of mefloquine and if so how did they do so; ( m ) what responsibility prior to the licensing of mefloquine did the Canadian Forces have under the Lariam Safety Monitoring Study and the Food and Drug Act to the Health Protection Branch; ( n ) did the Canadian Forces fulfil their pre-licensing responsibilities to the Health Protection Branch under the Lariam Safety Monitoring Study and the Food and Drug Act and if so how did they comply; ( o ) what action did the Health Protection Branch take in regard to the manufacturer on becoming aware that mefloquine had been administered to Canadian Forces in association with subsequent unexpected bizarre homicidal/suicidal behaviour; ( p ) what action did the Health Protection take in regard to the Canadian Forces and Dr. Martin Tepper on becoming aware that mefloquine had been administered to Canadian Forces in association with subsequent unexpected bizarre homicidal/suicidal behaviour; ( q ) what disciplinary action is provided for under the Lariam Safety Monitoring Study and the Food and Drug Act for failure of the manufacturer to comply; ( r ) what disciplinary action was taken against the manufacturer for failure to comply with the requirements of the Lariam Safety Monitoring Study and the Food and Drug Act; ( s ) what disciplinary action was provided for under the Lariam Safety Monitoring Study and the Food and Drug Act for Dr. Martin Tepper or others in the Canadian Forces who failed to comply; ( t ) what disciplinary action was taken by the Health Protection Branch against Dr. Martin Tepper or others in the Canadian Forces for failure to comply with the requirements of the Lariam Safety Monitoring Study and the Food and Drug Act during the pre-licensing period; ( u ) what action was taken by the Health Protection Branch to remedy the failure to comply with the reporting requirements of the Lariam Safety Monitoring Study and the Food and Drug Act; ( v ) did the Health Protection Branch investigate to determine the nature of the adverse reactions that occurred among Canadian Forces personnel; ( w ) what action did the Health Protection Branch take to ensure that the reporting deficiencies in the Lariam Safety Monitoring Study were accounted for in the Study's final analysis of the drug; and ( x ) as a result of the Canadian Forces experience in Somalia with mefloquine, what measures to date has the Health Protection Branch taken to assess the accuracy of the information regarding the nature and frequency of behavioral and neuropsychiatric effects of mefloquine provided to Canadian physicians, in accordance with the Food and Drug Act?
Return tabled.